Orexigen Revisited: Chances for Contrave Approval Seem Slim (OREX, $1.37)Wednesday, August 10, 2011 · 1:36 pm |
|
Orexigen Receives Crushing News That FDA Will Require Extremely Large Cardiovascular Outcomes Study In Order for Contrave To Gain Approval (OREX, $1.83)Sunday, June 5, 2011 · 3:31 pm |
|
Company Reports Success in Four Phase III Trials (OREX, $4.23)Saturday, June 4, 2011 · 8:34 am |
|
Going Over the Outlook with the New CEO, Mike Narachi (OREX, $5.32)Saturday, June 4, 2011 · 8:28 am |
|
Thoughts on Upcoming Advisory Meeting on Contrave (OREX, $5.40)Saturday, June 4, 2011 · 8:16 am |
|
|
There are 5 reports on file. |
